Taizong Biotech: Announcement Regarding Termination of OTC Trading and Listing on Taiwan Stock Exchange
Taizong Biotech announced that its stock will terminate OTC trading and be listed on the Taiwan Stock Exchange starting April 8, 115. The company is also conducting a cash capital increase prior to its IPO.
📋 Article Processing Timeline
- 📰 Published: April 7, 2026 at 09:00
- 🔍 Collected: April 8, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: April 19, 2026 at 03:09 (259h 9m after Collected)
1. Date of Fact Occurrence: 115/04/07
2. Reason for Suspension or Termination of Registration as OTC Stock: Transfer to Taiwan Stock Exchange for listing and trading.
3. Expected or Actual Date of Suspension or Termination of Registration as OTC Stock: 115/04/08
4. Other matters to be noted:
(1) Taizong Biotech's application for initial listing has been approved by the Taiwan Stock Exchange Corporation on December 23, 114 (Letter No. Tai Zheng Shang Yi Zi No. 1141805518).
(2) To facilitate the public offering prior to the initial listing, Taizong Biotech is conducting a cash capital increase of NT$73,830,000, issuing 7,383,000 ordinary shares at a face value of NT$10 per share. This has been filed and become effective with the Taiwan Stock Exchange Corporation on January 9, 115 (Letter No. Tai Zheng Shang Yi Zi No. 1151800090).
(3) Taizong Biotech has negotiated with the Taiwan Stock Exchange Corporation to set the listing and trading commencement date as April 8, 115, and will terminate OTC trading from the same day.
2. Reason for Suspension or Termination of Registration as OTC Stock: Transfer to Taiwan Stock Exchange for listing and trading.
3. Expected or Actual Date of Suspension or Termination of Registration as OTC Stock: 115/04/08
4. Other matters to be noted:
(1) Taizong Biotech's application for initial listing has been approved by the Taiwan Stock Exchange Corporation on December 23, 114 (Letter No. Tai Zheng Shang Yi Zi No. 1141805518).
(2) To facilitate the public offering prior to the initial listing, Taizong Biotech is conducting a cash capital increase of NT$73,830,000, issuing 7,383,000 ordinary shares at a face value of NT$10 per share. This has been filed and become effective with the Taiwan Stock Exchange Corporation on January 9, 115 (Letter No. Tai Zheng Shang Yi Zi No. 1151800090).
(3) Taizong Biotech has negotiated with the Taiwan Stock Exchange Corporation to set the listing and trading commencement date as April 8, 115, and will terminate OTC trading from the same day.